TriSalus Life Sciences, Inc.
TLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $19 | $12 | $8 |
| % Growth | 59% | 49.3% | 47.6% | – |
| Cost of Goods Sold | $4 | $3 | $2 | $1 |
| Gross Profit | $25 | $16 | $10 | $7 |
| % Margin | 86.1% | 85.9% | 81.8% | 85.8% |
| R&D Expenses | $18 | $30 | $21 | $14 |
| G&A Expenses | $18 | $24 | $12 | $9 |
| SG&A Expenses | $44 | $41 | $25 | $17 |
| Sales & Mktg Exp. | $26 | $17 | $13 | $8 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61 | $70 | $47 | $31 |
| Operating Income | -$36 | -$54 | -$36 | -$24 |
| % Margin | -122.9% | -294.3% | -293.9% | -286.1% |
| Other Income/Exp. Net | $6 | -$5 | -$11 | -$5 |
| Pre-Tax Income | -$30 | -$59 | -$47 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$33 | -$59 | -$47 | -$29 |
| % Margin | -112.9% | -320.7% | -380.6% | -343.4% |
| EPS | -1.25 | -2.23 | -1.59 | -0.92 |
| % Growth | 43.9% | -40.3% | -72.8% | – |
| EPS Diluted | -1.25 | -2.23 | -1.59 | -0.92 |
| Weighted Avg Shares Out | 27 | 26 | 30 | 31 |
| Weighted Avg Shares Out Dil | 27 | 26 | 30 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $0 | $0 | $2 |
| Depreciation & Amortization | -$3 | $1 | $0 | $0 |
| EBITDA | -$36 | -$59 | -$47 | -$24 |
| % Margin | -122.9% | -316.9% | -377.2% | -280.5% |